NO20070906L - Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat - Google Patents

Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat

Info

Publication number
NO20070906L
NO20070906L NO20070906A NO20070906A NO20070906L NO 20070906 L NO20070906 L NO 20070906L NO 20070906 A NO20070906 A NO 20070906A NO 20070906 A NO20070906 A NO 20070906A NO 20070906 L NO20070906 L NO 20070906L
Authority
NO
Norway
Prior art keywords
hyperphosphate
anemia
treating
lanthanum hydroxycarbonate
ckd
Prior art date
Application number
NO20070906A
Other languages
English (en)
Norwegian (no)
Inventor
Josephine Christine Ferdinando
David Gilmour
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of NO20070906L publication Critical patent/NO20070906L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20070906A 2004-07-27 2007-02-16 Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat NO20070906L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59110504P 2004-07-27 2004-07-27
PCT/US2005/026668 WO2006015055A1 (en) 2004-07-27 2005-07-27 Method of treating hyperphosphataemia using lanthanum hydroxycarbonate

Publications (1)

Publication Number Publication Date
NO20070906L true NO20070906L (no) 2007-04-23

Family

ID=35787449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070906A NO20070906L (no) 2004-07-27 2007-02-16 Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat

Country Status (14)

Country Link
US (1) US20060153932A1 (https=)
EP (1) EP1708723A4 (https=)
JP (1) JP4869229B2 (https=)
KR (2) KR20070054191A (https=)
CN (1) CN101018555A (https=)
AU (1) AU2005269362B2 (https=)
BR (1) BRPI0513603A (https=)
CA (1) CA2574450C (https=)
EA (1) EA010980B1 (https=)
MX (1) MX2007001114A (https=)
NO (1) NO20070906L (https=)
NZ (1) NZ552861A (https=)
WO (1) WO2006015055A1 (https=)
ZA (1) ZA200701707B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
EP1852695B1 (en) * 2006-05-05 2011-10-26 Shire International Licensing B.V. Assay for lanthanum hydroxy carbonate
US8961917B2 (en) * 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
GB201501000D0 (en) * 2015-01-21 2015-03-04 Univ Edinburgh Lanthanum thiosulfate and methods of preparation of the same
WO2017072256A1 (en) * 2015-10-27 2017-05-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Nicotinamide for lowering phosphate levels in hyperphosphatemia
KR101880447B1 (ko) * 2015-12-01 2018-07-23 김배용 생리활성물질 복합체, 이의 제조방법 및 이를 포함한 화장료 조성물
KR101684289B1 (ko) 2016-05-17 2016-12-09 한국식품연구원 락토바실러스 sp. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품
US10322409B1 (en) * 2018-03-05 2019-06-18 King Fahd University Of Petroleum And Minerals Low temperature hydrothermal method for the preparation of LaCO3OH nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592082A (en) * 1984-08-10 1986-05-27 The United States Of America As Represented By The United States Department Of Energy Quantitative determination of mineral composition by powder X-ray diffraction
CA2117351C (en) * 1992-01-13 1998-03-03 Julian Belknap Lo Preparation of tablets of increased strength
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
US5435986A (en) * 1994-08-30 1995-07-25 Industrial Technology Research Institute Method for preparing high purity aluminum hydroxide
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
AU782304B2 (en) * 1999-09-02 2005-07-14 Acologix, Inc. Methods and compositions for reducing serum phosphate levels
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
DK1389102T3 (da) * 2001-04-23 2011-06-06 Shire Int Licensing Bv Anvendelse af lanthancarbonat til forebyggelse af nyresten
US7469036B2 (en) * 2002-04-19 2008-12-23 Los Alamos National Security, Llc Analysis of macromolecules, ligands and macromolecule-ligand complexes
AU2003229437A1 (en) * 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.

Also Published As

Publication number Publication date
ZA200701707B (en) 2008-10-29
CN101018555A (zh) 2007-08-15
MX2007001114A (es) 2007-07-11
AU2005269362A1 (en) 2006-02-09
CA2574450C (en) 2011-07-19
KR20070054191A (ko) 2007-05-28
WO2006015055A1 (en) 2006-02-09
US20060153932A1 (en) 2006-07-13
EP1708723A1 (en) 2006-10-11
EA200700273A1 (ru) 2007-08-31
JP4869229B2 (ja) 2012-02-08
KR101072196B1 (ko) 2011-10-10
EA010980B1 (ru) 2008-12-30
KR20090023743A (ko) 2009-03-05
CA2574450A1 (en) 2006-02-09
JP2008508297A (ja) 2008-03-21
AU2005269362B2 (en) 2010-08-12
BRPI0513603A (pt) 2008-05-13
NZ552861A (en) 2010-11-26
EP1708723A4 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
NO20070906L (no) Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat
NO20075821L (no) Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
NO20090156L (no) Humanisert antistoff
MX387264B (es) Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
NO20083793L (no) Antistoffer mot amyloid-beta peptid
BR112014011670A2 (pt) anticorpo anti- adrenomedulina (adm) ou fragmento de anticorpo anti -adm ou uma estrutura anti- adm não-ig para utilização em terapia
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
BR112013021236A8 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
WO2006034465A8 (en) Memantine for the treatment of childhood behavioral disorders
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2009057119A3 (en) Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
ECSP10010266A (es) Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo[b,e]oxepina
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
CY1112620T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων
NO20070127L (no) Fremgangsmate for behandling av granuloma annulare eller sarkoid
NO20064964L (no) Behandling av svekket respiratorisk funksjon
NO20051669L (no) Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner
Pyo et al. Factors related to blood glucose control in patients with diabetes
TW200727905A (en) Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
NO20091659L (no) Fremgangsmater for behandling av disruptive oppforselsforstyrrelser
WO2021074786A3 (en) Non-hemolytic compositions and methods of use for recovering disease causing toxic constituents in the blood

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application